{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:40:57Z","timestamp":1792186857974,"version":"4.4.0"},"reference-count":107,"publisher":"Impact Journals, LLC","issue":"37","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,9,13]]},"DOI":"10.18632\/oncotarget.10858","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T23:47:00Z","timestamp":1469576820000},"page":"60712-60722","source":"Crossref","is-referenced-by-count":119,"title":["Triple negative breast cancer: shedding light onto the role of pi3k\/akt\/mtor pathway"],"prefix":"10.18632","volume":"7","author":[{"given":"Daniela","family":"Massihnia","sequence":"first","affiliation":[{"name":"Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Galvano","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Fanale","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Perez","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Castiglia","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Incorvaia","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"List\u00ec","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cicero","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Bazan","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Castorina","sequence":"additional","affiliation":[{"name":"Fondazione Mediterranea \u201cG.B. Morgagni\u201d, Catania, Italy"},{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,7,26]]},"reference":[{"issue":"17","key":"1","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/onc.2011.408","article-title":"Breast cancer genome-wide association studies: there is strength in numbers","volume":"31","author":"Russo","year":"2012","journal-title":"Oncogene"},{"issue":"6797","key":"2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Borresen-Dale","year":"2000","journal-title":"Nature"},{"issue":"3","key":"3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10549-013-2649-0","article-title":"HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions","volume":"140","author":"Russo","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"4","first-page":"746858","article-title":"Hypoxia and human genome stability: downregulation of BRCA2 expression in breast cancer cell lines","volume":"2013","author":"Russo","year":"2013","journal-title":"Biomed Res Int"},{"key":"5","doi-asserted-by":"crossref","DOI":"10.1373\/clinchem.2015.253229","article-title":"The Impact of Gene Expression Patterns in Breast Cancer","author":"Sorlie","year":"2016","journal-title":"Clin Chem"},{"key":"6","article-title":"Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes","author":"Blomqvist","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"7","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.3390\/cancers6042187","article-title":"Standard of care and promising new agents for triple negative metastatic breast cancer","volume":"6","author":"Mezi","year":"2014","journal-title":"Cancers (Basel)"},{"issue":"3 Suppl","key":"8","doi-asserted-by":"crossref","first-page":"162S","DOI":"10.1177\/1066896910370771","article-title":"Will molecular classification replace traditional breast pathology?","volume":"18","author":"Schnitt","year":"2010","journal-title":"Int J Surg Pathol"},{"issue":"4","key":"9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/1066896908328577","article-title":"Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?","volume":"17","author":"Reis-Filho","year":"2009","journal-title":"Int J Surg Pathol"},{"issue":"8","key":"10","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies\u2014improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015","volume":"26","author":"Senn","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2011.36.1196","article-title":"PI3K\/AKT\/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations","volume":"30","author":"Kurzrock","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"12","first-page":"649","article-title":"Triple negative breast cancer: a difficult disease to diagnose and treat","volume":"30","author":"Gomez","year":"2013","journal-title":"Rev Peru Med Exp Salud Publica"},{"issue":"4","key":"13","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1309\/AJCPQN8GZ8SILKGN","article-title":"Triple-negative breast carcinoma: current and emerging concepts","volume":"141","author":"Singh","year":"2014","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"14","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Perou","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.22836","article-title":"Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database","volume":"110","author":"Mitchell","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/annonc\/mdu498","article-title":"Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival","volume":"26","author":"Lindstrom","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"17","first-page":"67","article-title":"Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?","volume":"113","author":"Bazan","year":"2008","journal-title":"Breast Cancer Research and Treatment"},{"issue":"Suppl 2","key":"18","first-page":"S73","article-title":"Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer","volume":"9","author":"Carey","year":"2009","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"19","first-page":"312","article-title":"Biological subtypes of breast cancer: current concepts and implications for recurrence patterns","volume":"57","author":"Morris","year":"2013","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"20","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.5604\/17322693.1077713","article-title":"Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches","volume":"67","author":"Krajewska","year":"2013","journal-title":"Postepy Hig Med Dosw (Online)"},{"issue":"12","key":"21","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s40265-013-0091-6","article-title":"Relapsed triple-negative breast cancer: challenges and treatment strategies","volume":"73","author":"Conte","year":"2013","journal-title":"Drugs"},{"issue":"8","key":"22","first-page":"806","article-title":"Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas","volume":"5","author":"Hsueh","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10549-015-3491-3","article-title":"The prognostic impact of age in different molecular subtypes of breast cancer","volume":"152","author":"Karn","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/0973-1482.154000","article-title":"Evaluation of treatment outcomes of triple-negative breast cancer","volume":"12","author":"Sengul","year":"2016","journal-title":"J Cancer Res Ther"},{"issue":"1","key":"25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/1535-7163.MCT-12-0781","article-title":"Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities","volume":"12","author":"Koeman","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 2","key":"26","first-page":"S3","article-title":"Triple-negative breast cancer","volume":"12","author":"Costanzo","year":"2010","journal-title":"Breast Cancer Res"},{"issue":"27","key":"27","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","article-title":"Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND. 163","volume":"27","author":"McIntosh","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"28","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Pietenpol","year":"2011","journal-title":"J Clin Invest"},{"issue":"2","key":"29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1158\/1078-0432.CCR-09-1091","article-title":"Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation","volume":"16","author":"Schneider","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"4","key":"30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1470-2045(10)70018-8","article-title":"Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials","volume":"11","author":"Swanton","year":"2010","journal-title":"Lancet Oncol"},{"key":"31","first-page":"690916","article-title":"Stabilizingdestabilizing the microtubules: a double-edge sword for an effective cancer treatment option?","volume":"2015","author":"Cicero","year":"2015","journal-title":"Anal Cell Pathol (Amst)"},{"key":"32","article-title":"BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane","author":"Endo","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"13","key":"33","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1158\/1078-0432.CCR-07-4379","article-title":"Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast","volume":"14","author":"Kleer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jsbmb.2012.08.007","article-title":"Androgen receptor in triple negative breast cancer","volume":"133","author":"Sasano","year":"2013","journal-title":"J Steroid Biochem Mol Biol"},{"key":"35","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12672-015-0232-3","article-title":"Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease","volume":"6","author":"Richer","year":"2015","journal-title":"Horm Cancer"},{"issue":"3","key":"36","first-page":"186","article-title":"Role of the androgen receptor in triple-negative breast cancer","volume":"14","author":"O'Regan","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"issue":"3","key":"37","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1158\/1535-7163.MCT-14-0926","article-title":"Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide","volume":"14","author":"Richer","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"38","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/1471-2407-14-302","article-title":"Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling","volume":"14","author":"Ocana","year":"2014","journal-title":"BMC Cancer"},{"issue":"7403","key":"39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10933","article-title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","volume":"486","author":"Bernard","year":"2012","journal-title":"Nature"},{"issue":"2","key":"40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/modpathol.2010.200","article-title":"Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists","volume":"24","author":"Tse","year":"2011","journal-title":"Mod Pathol"},{"issue":"Suppl 6","key":"41","first-page":"56","article-title":"Emerging targeted therapies in triple-negative breast cancer","volume":"23","author":"Gullo","year":"2012","journal-title":"Ann Oncol"},{"issue":"Suppl 7","key":"42","first-page":"30","article-title":"Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?","volume":"21","author":"Andre","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1524-4741.2011.01175.x","article-title":"The paradox of triple negative breast cancer: novel approaches to treatment","volume":"18","author":"Fumoleau","year":"2012","journal-title":"Breast J"},{"issue":"19","key":"44","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"Ueno","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10549-014-2876-z","article-title":"The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis","volume":"144","author":"Barni","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"46","first-page":"106","article-title":"Current approaches in treatment of triple-negative breast cancer","volume":"12","author":"El-Hadaad","year":"2015","journal-title":"Cancer Biol Med"},{"issue":"Suppl 1","key":"47","first-page":"E16","article-title":"Novel treatment approaches for triple-negative breast cancer","volume":"10","author":"Ford","year":"2010","journal-title":"Clin Breast Cancer"},{"issue":"17","key":"48","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1111\/bph.13211","article-title":"Therapeutic targets of triple-negative breast cancer: a review","volume":"172","author":"Sinha","year":"2015","journal-title":"Br J Pharmacol"},{"key":"49","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1038\/emm.2014.127","article-title":"beta-TrCP1 degradation is a novel action mechanism of PI3K\/mTOR inhibitors in triple-negative breast cancer cells","volume":"47","author":"Bae","year":"2015","journal-title":"Exp Mol Med"},{"issue":"9","key":"50","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/annonc\/mds067","article-title":"Targeting triple-negative breast cancer: optimising therapeutic outcomes","volume":"23","author":"Verma","year":"2012","journal-title":"Ann Oncol"},{"key":"51","article-title":"A headlight on liquid biopsies: a challenging tool for breast cancer management","author":"Russo","year":"2016","journal-title":"Tumour Biol"},{"issue":"5853","key":"52","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1126\/science.1145720","article-title":"The genomic landscapes of human breast and colorectal cancers","volume":"318","author":"Nikolsky","year":"2007","journal-title":"Science"},{"key":"53","article-title":"Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?","author":"Russo","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"54","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ctrv.2012.11.002","article-title":"Defining biomarkers to predict sensitivity to PI3K\/Akt\/mTOR pathway inhibitors in breast cancer","volume":"39","author":"Blumenschein","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","article-title":"The PI3K\/AKT Pathway as a Target for Cancer Treatment","volume":"67","author":"Arteaga","year":"2016","journal-title":"Annu Rev Med"},{"issue":"Suppl 1","key":"56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1634\/theoncologist.2011-S1-12","article-title":"Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer","volume":"16","author":"Baselga","year":"2011","journal-title":"Oncologist"},{"key":"57","article-title":"Dietary restriction: could it be considered as speed bump on tumor progression road?","author":"Russo","year":"2016","journal-title":"Tumour Biol"},{"issue":"2","key":"58","first-page":"197","article-title":"Role of Notch and its oncogenic signaling crosstalk in breast cancer","volume":"1815","author":"Gonzalez-Perez","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"41","key":"59","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1038\/onc.2008.244","article-title":"Class I PI3K in oncogenic cellular transformation","volume":"27","author":"Vogt","year":"2008","journal-title":"Oncogene"},{"issue":"6","key":"60","doi-asserted-by":"crossref","first-page":"670","DOI":"10.6004\/jnccn.2013.0086","article-title":"The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer","volume":"11","author":"Wolff","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"61","doi-asserted-by":"crossref","first-page":"L666","DOI":"10.1152\/ajplung.90548.2008","article-title":"Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension","volume":"297","author":"Yuan","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"8","key":"62","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1158\/1078-0432.CCR-10-2289","article-title":"Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma","volume":"17","author":"Dorigo","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"3","key":"63","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cell.2008.04.013","article-title":"Tenets of PTEN tumor suppression","volume":"133","author":"Pandolfi","year":"2008","journal-title":"Cell"},{"issue":"4","key":"64","doi-asserted-by":"publisher","first-page":"321","DOI":"10.18632\/oncotarget.260","article-title":"INPP4B: the new kid on the PI3K block","volume":"2","author":"Ittmann","year":"2011","journal-title":"Oncotarget"},{"key":"65","doi-asserted-by":"crossref","unstructured":"Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61\u201370.","DOI":"10.1038\/nature11412"},{"issue":"3","key":"66","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbapap.2009.12.001","article-title":"Dissecting the role of mTOR: lessons from mTOR inhibitors","volume":"1804","author":"Sonenberg","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Sabatini","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"68","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1074\/jbc.M807532200","article-title":"S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation","volume":"284","author":"Holz","year":"2009","journal-title":"J Biol Chem"},{"issue":"4","key":"69","first-page":"361","article-title":"S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer","volume":"6","author":"Hung","year":"2014","journal-title":"Am J Transl Res"},{"issue":"2","key":"70","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-15-1640-T","article-title":"Treatment of Triple-Negative Breast Cancer with TORC1\/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population","volume":"76","author":"Arteaga","year":"2016","journal-title":"Cancer Res"},{"issue":"2","key":"71","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/onc.2012.572","article-title":"Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer","volume":"33","author":"Pandiella","year":"2014","journal-title":"Oncogene"},{"issue":"2","key":"72","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.breast.2011.09.008","article-title":"mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors","volume":"21","author":"Duffy","year":"2012","journal-title":"Breast"},{"issue":"5","key":"73","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s13058-014-0434-6","article-title":"Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential","volume":"16","author":"Huang","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"4","key":"74","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1758834014530023","article-title":"The PI3K\/AKT\/mTOR pathway in breast cancer: targets, trials and biomarkers","volume":"6","author":"O'Regan","year":"2014","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"75","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/j.1349-7006.2012.02359.x","article-title":"Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells","volume":"103","author":"Tamura","year":"2012","journal-title":"Cancer Sci"},{"key":"76","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/OTT.S67673","article-title":"Triple-negative breast cancer: new perspectives for targeted therapies","volume":"8","author":"Tomao","year":"2015","journal-title":"Onco Targets Ther"},{"issue":"24 Supplement","key":"77","article-title":"Abstract PD1-6: A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II\/III triple-negative breast cancer (TNBC)","volume":"73","author":"Chen","year":"2014","journal-title":"Cancer Research"},{"key":"78","first-page":"43","article-title":"Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes","volume":"6","author":"Collignon","year":"2014","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"6","key":"79","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/annonc\/mdu124","article-title":"Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FECthe combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancerdagger","volume":"25","author":"Flores","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"80","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/bcr3634","article-title":"Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer","volume":"16","author":"Adams","year":"2014","journal-title":"Breast Cancer Res"},{"key":"81","article-title":"Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer","author":"Solomayer","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"82","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2559.2007.02889.x","article-title":"Triple negative tumours: a critical review","volume":"52","author":"Tutt","year":"2008","journal-title":"Histopathology"},{"issue":"8","key":"83","article-title":"Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer","volume":"108","author":"FitzGerald","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"84","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1517\/14712598.2015.1071348","article-title":"Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?","volume":"15","author":"Russo","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"85","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/bcr3064","article-title":"Current approaches to the management of Her2-negative metastatic breast cancer","volume":"14","author":"DeMichele","year":"2012","journal-title":"Breast Cancer Res"},{"issue":"16","key":"86","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","article-title":"Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition","volume":"65","author":"Khuri","year":"2005","journal-title":"Cancer Res"},{"issue":"2 Supplement","key":"87","first-page":"407","article-title":"A phase II trial of a mammalian target of rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer","volume":"69","author":"Fleming","year":"2014","journal-title":"Cancer Research"},{"key":"88","article-title":"Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain","author":"Jiang","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"89","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/1535-7163.MCT-10-0925","article-title":"Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells","volume":"10","author":"O'Regan","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"90","doi-asserted-by":"crossref","first-page":"R36","DOI":"10.1186\/bcr3640","article-title":"Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition","volume":"16","author":"Larijani","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"2","key":"91","first-page":"207","article-title":"Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells","volume":"1825","author":"Gonzalez-Perez","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"92","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-014-3102-8","article-title":"Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer","volume":"147","author":"Boerner","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"93","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/bcr3618","article-title":"Clinical development of mTOR inhibitors in breast cancer","volume":"16","author":"Andre","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"7","key":"94","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdv163","article-title":"Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer","volume":"26","author":"Kurzrock","year":"2015","journal-title":"Ann Oncol"},{"key":"95","article-title":"Review of PI3K\/mTOR inhibitors entering clinical trials to treat triple negative breast cancers","author":"Legembre","year":"2016","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"15","key":"96","article-title":"Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer","volume":"32","author":"Hershman","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"97","first-page":"203","article-title":"Clinical potential of novel therapeutic targets in breast cancer: CDK4\/6, Src, JAK\/STAT, PARP, HDAC, and PI3K\/AKT\/mTOR pathways","volume":"7","author":"Miller","year":"2014","journal-title":"Pharmgenomics Pers Med"},{"issue":"9737","key":"98","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Carmichael","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"99","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"de Bono","year":"2009","journal-title":"N Engl J Med"},{"issue":"7035","key":"100","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Ashworth","year":"2005","journal-title":"Nature"},{"issue":"16","key":"101","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"Ashworth","year":"2006","journal-title":"Cancer Res"},{"issue":"15","key":"102","article-title":"Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer","volume":"28","author":"Oza","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"103","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","volume":"2","author":"Perez","year":"2012","journal-title":"Cancer Discov"},{"key":"104","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biopha.2015.08.031","article-title":"Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line","volume":"75","author":"Seow","year":"2015","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"105","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2012.01.015","article-title":"Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition","volume":"319","author":"Hedenfalk","year":"2012","journal-title":"Cancer Lett"},{"key":"106","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13058-015-0560-9","article-title":"Molecular characterization and targeted therapeutic approaches in breast cancer","volume":"17","author":"Cristofanilli","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"12","key":"107","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrclinonc.2010.154","article-title":"Triple-negative breast cancer: disease entity or title of convenience?","volume":"7","author":"Gianni","year":"2010","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T01:32:30Z","timestamp":1749000750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,26]]},"references-count":107,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2016,9,13]]}},"alternative-id":["10858","27474173"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.10858","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,26]]}}}